Abstract
There is an urgent need for inexpensive, population-wide surveillance testing for COVID-19. We tested newborn dried blood spots (DBS) anti-SARS-COV-2 antibodies for all infants born at Yale from March-May 2020, and found that newborn DBS serologies reflect maternal and population-wide infection rates during the study period. This suggests a role for DBS in COVID-19 surveillance in areas where viral testing is limited.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Yale Human Research Protection Program Institutional Review Boards Investigator: Shelli Farhadian Type of Review:Not Human Subject Research Determination Title of Study:COVID-19 surveillance using newborn dried bloodspots IRB Protocol ID:2000028550
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data stored on HIPAA-secure server; access may be available upon request
